Product Data Sheet

NVP-BEP800

Cat. No.: A4064
CAS No.: 847559-80-2
Formula: C21H23Cl2N5O2S
M.Wt: 480.4
Synonyms:
Target: Proteases
Pathway: HSP
Storage: Store at -20°C



Solvent & Solubility

In Vitro

insoluble in H2O; ⩾16 mg/mL in EtOH with gentle warming; ⩾24.7 mg/mL in DMSO with gentle warming and ultrasonic

Preparing Stock Solutions

Mass / Solvent / Concentration	1mg	5mg	10mg
1 mM	2.0816 mL	10.4080 mL	20.8160 mL
5 mM	0.4163 mL	2.0816 mL	4.1632 mL
10 mM	0.2082 mL	1.0408 mL	2.0816 mL

Please refer to the solubility information to select the appropriate solvent.

Biological Activity

Shortsummary	Oral Hsp90β inhibitor, novel, fully synthetic
IC_{50} & Target	58 nM (Hsp90β)

In Vitro

Cell Viability Assay

Cell Line:	BT-474 cells
Preparation method：	The solubility of this compound in DMSO is limited. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20 °C for several months.

	Reacting conditions:	50 ~ 500 nM; 24 hrs
	Applications:	In BT-474 cells, NVP-BEP800 concentration-dependently decreased phospho-Akt (Ser473) and ErbB2 levels. At the dose of 500 nM, phosphorylation of Akt at Ser473 was not detectable, and lower levels of Akt and ErbB2 were also detected.
In Vivo	**Animal experiment**	
	Animal models:	Mice bearing breast cancer BT-474 cell xenografts
	Dosage form:	15 or 30 mg/kg/day; p.o.
	Applications:	In mice bearing breast cancer BT-474 cell xenografts, NVP-BEP800 dose-dependently increased Hsp90-p23 complex dissociation and lowered the levels of steady-state ErbB2, phospho-Akt as well as phospho-S6. NVP-BEP800 induced 38% tumor regression at dose of 30 mg/kg/day and a T/C value of 36% at dose of 15 mg/kg/day.
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

Product Citations

See more customer validations on www.apexbt.com.

References

[1]. Massey AJ, Schoepfer J, Brough PA, Brueggen J, Chène P, Drysdale MJ, Pfaar U, Radimerski T, Ruetz S, Schweitzer A, Wood M, Garcia-Echeverria C, Jensen MR. Preclinical antitumor activity of the orally available heat shock protein 90 inhibitor NVP-BEP800. Mol Cancer Ther. 2010 Apr;9(4):906-19.

Caution

FOR RESEARCH PURPOSES ONLY.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.

APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com